Lars N. G. Nilsson

Lars N. G. Nilsson

Auto-generated profile, based on publicly available information

Lars N. G. Nilsson

Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
KNKaja Nordengen
Kaja Nordengen
BKBjørn-Eivind Kirsebom
Bjørn-Eivind Kirsebom
KHKristi Henjum
Kristi Henjum
PSPer Selnes
Per Selnes
BGBerglind Gísladóttir
Berglind Gísladóttir
TFTormod Fladby
Tormod Fladby
Neuronal and glial cell interaction is essential for synaptic homeostasis and may be affected in Alzheimer’s disease (AD). We measured cerebrospinal fluid (CSF) neuronal and glia markers along the AD continuum, to reveal putative protective or harmful stage-dependent patterns of activation. We included healthy controls (n = 36) and Aβ-positive (Aβ+) cases (as defined by pathological CSF amyloid beta 1-42 (Aβ42)) with either subjective cognitive decline (SCD, n = 19), mild cognitive impairment (MCI, n = 39), or AD dementia (n = 27). The following CSF markers were measured: a microglial activation marker—soluble triggering receptor expressed on myeloid cells 2 (sTREM2), a marker of microglial inflammatory reaction—monocyte chemoattractant protein-1 (MCP-1), two astroglial activation markers—chitinase-3-like protein 1 (YKL-40) and clusterin, a neuron-microglia communication marker—fractalkine, and the CSF AD biomarkers (Aβ42, phosphorylated tau (P-tau), total tau (T-tau)). Using ANOVA with planned comparisons, or Kruskal-Wallis tests with Dunn’s pairwise comparisons, CSF levels were compared between clinical groups and between stages of biomarker severity using CSF biomarkers for classification based on amyloid pathology (A), tau pathology (T), and neurodegeneration (N) giving rise to the A/T/N score. Compared to healthy controls, sTREM2 was increased in SCD (p < .01), MCI (p < .05), and AD dementia cases (p < .001) and increased in AD dementia compared to MCI cases (p < .05). MCP-1 was increased in MCI (p < .05) and AD dementia compared to both healthy controls (p < .001) and SCD cases (p < .01). YKL-40 was increased in dementia compared to healthy controls (p < .01) and MCI (p < .05). All of the CSF activation markers were increased in subjects with pathological CSF T-tau (A+T−N+ and A+T+N+), compared to subjects without neurodegeneration (A−T−N− and A+T−N−). Microglial activation as indicated by increased sTREM2 is present already at the preclinical SCD stage; increased MCP-1 and astroglial activation markers (YKL-40 and clusterin) were noted only at the MCI and AD dementia stages, respectively, and in Aβ+ cases (A+) with pathological T-tau (N+). Possible different effects of early and later glial activation need to be explored.

9 June 2007 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
HEHillevi Englund
Hillevi Englund
DSDag Sehlin
Dag Sehlin
AJAnn‐Sofi Johansson
Ann‐Sofi Johansson
LNLars N. G. Nilsson
Lars N. G. Nilsson
PGPär Gellerfors
Pär Gellerfors
FPFrida Ekholm Pettersson
Frida Ekholm Pettersson

1 March 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JRJack Rogers
Jack Rogers
LLLorene M. Leiter
Lorene M. Leiter
JMJay McPhee
Jay McPhee
CCCatherine M. Cahill
Catherine M. Cahill
SZShan-Shan Zhan
Shan-Shan Zhan
LNLars N. G. Nilsson
Lars N. G. Nilsson
The amyloid precursorprotein (APP) has been associated with Alzheimer’s disease (AD) because APP is processed into the β-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD. Inflammation is also associated with AD as exemplified by increased expression of interleukin-1 (IL-1) in microglia in affected areas of the AD brain. Here we demonstrate that IL-1α and IL-1β increase APP synthesis by up to 6-fold in primary human astrocytes and by 15-fold in human astrocytoma cells without changing the steady-state levels of APP mRNA. A 90-nucleotide sequence in the APP gene 5′-untranslated region (5′-UTR) conferred translational regulation by IL-1α and IL-1β to a chloramphenicol acetyltransferase (CAT) reporter gene. Steady-state levels of transfected APP(5′-UTR)/CAT mRNAs were unchanged, whereas both base-line and IL-1-dependent CAT protein synthesis were increased. This APP mRNA translational enhancer maps from +55 to +144 nucleotides from the 5′-cap site and is homologous to related translational control elements in the 5′-UTR of the light and and heavy ferritin genes. Enhanced translation of APP mRNA provides a mechanism by which IL-1 influences the pathogenesis of AD.

1 January 2006 in Neurobiology of Aging
Verified
Journal Article
Closed access
ALAnna Lord
Anna Lord
HKHannu Kalimo
Hannu Kalimo
CEChris Eckman
Chris Eckman
XZXiao-Qun Zhang
Xiao-Qun Zhang
LLLars Lannfelt
Lars Lannfelt
LNLars N.G. Nilsson
Lars N.G. Nilsson

12 December 2011 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JYJing Yang
Jing Yang
LLLisa K. Lunde
Lisa K. Lunde
PNPaworn Nuntagij
Paworn Nuntagij
TOTomohiro Oguchi
Tomohiro Oguchi
LCLaura M.A. Camassa
Laura M.A. Camassa
RTReidun Torp
Reidun Torp
Aquaporin-4 (AQP4) is the predominant water channel in brain and is selectively expressed in astrocytes. Astrocytic endfoot membranes exhibit tenfold higher densities of AQP4 than non-endfoot membranes, making AQP4 an excellent marker of astrocyte polarization. Loss of astrocyte polarization is known to compromise astrocytic function and to be associated with impaired water and K + homeostasis. Here we investigate by a combination of light and electron microscopic immunocytochemistry whether amyloid deposition is associated with a loss of astrocyte polarization, using AQP4 as a marker. We used the tg-ArcSwe mouse model of Alzheimer's disease, as this model displays perivascular plaques as well as plaques confined to the neuropil. 3D reconstructions were done to establish the spatial relation between plaques and astrocytic endfeet, the latter known to contain the perivascular pool of AQP4. Changes in AQP4 expression emerge just after the appearance of the first plaques. Typically, there is a loss of AQP4 from endfoot membranes at sites of perivascular amyloid deposits, combined with an upregulation of AQP4 in the neuropil surrounding plaques. By electron microscopy it could be verified that the upregulation reflects an increased concentration of AQP4 in those delicate astrocytic processes that abound in synaptic regions. Thus, astrocytes exhibit a redistribution of AQP4 from endfoot membranes to non-endfoot membrane domains. The present data suggest that the development of amyloid deposits is associated with a loss of astrocyte polarization. The possible perturbation of water and K + homeostasis could contribute to cognitive decline and seizure propensity in patients with Alzheimer's disease.

1 August 2007 in ACS Chemical Biology
Verified
Journal Article
Closed access
KNK. Peter R. Nilsson
K. Peter R. Nilsson
AÅAndreas Åslund
Andreas Åslund
IBIna Berg
Ina Berg
SNSofie Nyström
Sofie Nyström
PKPeter Konradsson
Peter Konradsson
PHPer Hammarstrom
Per Hammarstrom